Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Sarcoma | Research article

A nomogram for determining the disease-specific survival in Ewing sarcoma: a population study

Authors: Jun Zhang, Zhenyu Pan, Jin Yang, Xiaoni Yan, Yuanjie Li, Jun Lyu

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

We aimed to develop and validate a nomogram for predicting the disease-specific survival of Ewing sarcoma (ES) patients.

Methods

The Surveillance, Epidemiology, and End Results (SEER) program database was used to identify ES from 1990 to 2015, in which the data was extracted from 18 registries in the US. Multivariate analysis performed using Cox proportional hazards regression models was performed on the training set to identify independent prognostic factors and construct a nomogram for the prediction of the 3-, 5-, and 10-year survival rates of patients with ES. The predictive values were compared by using concordance indexes (C-indexes), calibration plots, integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA).

Results

A total of 2,643 patients were identified. After multivariate Cox regression, a nomogram was established based on a new model containing the predictive variables of age, race, extent of disease, tumor size, and therapy of surgery. The new model provided better C-indexes (0.684 and 0.704 in the training and validation cohorts, respectively) than the model without therapy of surgery (0.661 and 0.668 in the training and validation cohorts, respectively). The good discrimination and calibration of the nomogram were demonstrated for both the training and validation cohorts. NRI and IDI were also improved. Finally, DCA demonstrated that the nomogram was clinically useful.

Conclusion

We developed a reliable nomogram for determining the prognosis and treatment outcomes of patients with ES in the US. However, the proposed nomogram still requires external data verification in future applications, especially for regions outside the US.
Literature
1.
go back to reference Rodriguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, Krasin MJ. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol. 2008;19(4):814–20.CrossRef Rodriguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, Krasin MJ. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol. 2008;19(4):814–20.CrossRef
2.
go back to reference Arshi A, Sharim J, Park DY, Park HY, Yazdanshenas H, Bernthal NM, Shamie AN. Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine. Spine J. 2017;17(5):645–55.CrossRef Arshi A, Sharim J, Park DY, Park HY, Yazdanshenas H, Bernthal NM, Shamie AN. Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine. Spine J. 2017;17(5):645–55.CrossRef
3.
go back to reference Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425–30.CrossRef Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425–30.CrossRef
4.
go back to reference Lin Z, Yan S, Zhang J, Pan Q. A nomogram for distinction and potential prediction of liver metastasis in breast Cancer patients. J Cancer. 2018;9(12):2098–106.CrossRef Lin Z, Yan S, Zhang J, Pan Q. A nomogram for distinction and potential prediction of liver metastasis in breast Cancer patients. J Cancer. 2018;9(12):2098–106.CrossRef
5.
go back to reference Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.CrossRef Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.CrossRef
6.
go back to reference Wu J, Sun H, Li J, Guo Y, Zhang K, Lang C, Zou C, Ma H. Increased survival of patients aged 0-29 years with osteosarcoma: a period analysis, 1984-2013. Cancer Med. 2018;7(8):3652–61.CrossRef Wu J, Sun H, Li J, Guo Y, Zhang K, Lang C, Zou C, Ma H. Increased survival of patients aged 0-29 years with osteosarcoma: a period analysis, 1984-2013. Cancer Med. 2018;7(8):3652–61.CrossRef
7.
go back to reference Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep. 2014;4:4227.CrossRef Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep. 2014;4:4227.CrossRef
8.
go back to reference Wang Z, Li S, Li Y, Lin N, Huang X, Liu M, Pan W, Yan X, Sun L, Li H, et al. Prognostic factors for survival among patients with primary bone sarcomas of small bones. Cancer Manag Res. 2018;10:1191–9.CrossRef Wang Z, Li S, Li Y, Lin N, Huang X, Liu M, Pan W, Yan X, Sun L, Li H, et al. Prognostic factors for survival among patients with primary bone sarcomas of small bones. Cancer Manag Res. 2018;10:1191–9.CrossRef
9.
go back to reference Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(2):189–95.CrossRef Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(2):189–95.CrossRef
10.
go back to reference Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., statistics in medicine (DOI: 10.1002/sim.2929). Stat Med. 2008;27(2):191–5.CrossRef Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., statistics in medicine (DOI: 10.1002/sim.2929). Stat Med. 2008;27(2):191–5.CrossRef
11.
go back to reference Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74.CrossRef Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74.CrossRef
12.
go back to reference Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol. 2001;19(6):1818–29.CrossRef Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol. 2001;19(6):1818–29.CrossRef
13.
go back to reference Krakorova DA, Kubackova K, Dusek L, Tomas T, Janicek P, Tucek S, Prausova J, Kiss I, Zambo I. Advantages in prognosis of adult patients with Ewing sarcoma: 11-years experiences and current treatment management. Pathol Oncol Res. 2018;24(3):623–30.CrossRef Krakorova DA, Kubackova K, Dusek L, Tomas T, Janicek P, Tucek S, Prausova J, Kiss I, Zambo I. Advantages in prognosis of adult patients with Ewing sarcoma: 11-years experiences and current treatment management. Pathol Oncol Res. 2018;24(3):623–30.CrossRef
14.
go back to reference Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115(7):1531–43.CrossRef Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115(7):1531–43.CrossRef
15.
go back to reference Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–46.CrossRef Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–46.CrossRef
16.
go back to reference Cheung MR. Optimization of predictors of Ewing sarcoma cause-specific survival: a population study. Asian Pac J Cancer Prev. 2014;15(10):4143–5.CrossRef Cheung MR. Optimization of predictors of Ewing sarcoma cause-specific survival: a population study. Asian Pac J Cancer Prev. 2014;15(10):4143–5.CrossRef
17.
go back to reference Campbell K, Shulman D, Janeway KA, DuBois SG. Comparison of epidemiology, clinical features, and outcomes of patients with reported Ewing sarcoma and PNET over 40 years justifies current WHO classification and treatment approaches. Sarcoma. 2018;2018:1712964.CrossRef Campbell K, Shulman D, Janeway KA, DuBois SG. Comparison of epidemiology, clinical features, and outcomes of patients with reported Ewing sarcoma and PNET over 40 years justifies current WHO classification and treatment approaches. Sarcoma. 2018;2018:1712964.CrossRef
18.
go back to reference Wan ZH, Huang ZH, Chen LB. Survival outcome among patients with Ewing’s sarcoma of bones and joints: a population-based cohort study. Sao Paulo Med J. 2018;136(2):116–22.CrossRef Wan ZH, Huang ZH, Chen LB. Survival outcome among patients with Ewing’s sarcoma of bones and joints: a population-based cohort study. Sao Paulo Med J. 2018;136(2):116–22.CrossRef
19.
go back to reference Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer. 2010;116(8):1964–73.CrossRef Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer. 2010;116(8):1964–73.CrossRef
20.
go back to reference Chakraborty D, Rangamani S, Kulothungan V, Chaturvedi M, Stephen S, Das P, Sudarshan KL, Janani Surya R, Sathish Kumar K, John A, et al. Trends in incidence of Ewing sarcoma of bone in India - evidence from the National Cancer Registry Programme (1982-2011). J Bone Oncol. 2018;12:49–53.CrossRef Chakraborty D, Rangamani S, Kulothungan V, Chaturvedi M, Stephen S, Das P, Sudarshan KL, Janani Surya R, Sathish Kumar K, John A, et al. Trends in incidence of Ewing sarcoma of bone in India - evidence from the National Cancer Registry Programme (1982-2011). J Bone Oncol. 2018;12:49–53.CrossRef
21.
go back to reference Grevener K, Haveman LM, Ranft A, van den Berg H, Jung S, Ladenstein R, Klco-Brosius S, Juergens H, Merks JH, Dirksen U. Management and outcome of Ewing sarcoma of the head and neck. Pediatr Blood Cancer. 2016;63(4):604–10.CrossRef Grevener K, Haveman LM, Ranft A, van den Berg H, Jung S, Ladenstein R, Klco-Brosius S, Juergens H, Merks JH, Dirksen U. Management and outcome of Ewing sarcoma of the head and neck. Pediatr Blood Cancer. 2016;63(4):604–10.CrossRef
22.
go back to reference Ataergin S, Ozet A, Solchaga L, Turan M, Beyzadeoglu M, Oysul K, Arpaci F, Komurcu S, Surenkok S, Ozturk M. Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. Med Oncol. 2009;26(3):276–86.CrossRef Ataergin S, Ozet A, Solchaga L, Turan M, Beyzadeoglu M, Oysul K, Arpaci F, Komurcu S, Surenkok S, Ozturk M. Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. Med Oncol. 2009;26(3):276–86.CrossRef
23.
go back to reference Akagunduz OO, Kamer SA, Kececi B, Demirag B, Oniz H, Kantar M, Cetingul N, Sabah D, Anacak Y. The role of radiotherapy in local control of nonextremity Ewing sarcomas. Tumori. 2016;102(2):162–7.CrossRef Akagunduz OO, Kamer SA, Kececi B, Demirag B, Oniz H, Kantar M, Cetingul N, Sabah D, Anacak Y. The role of radiotherapy in local control of nonextremity Ewing sarcomas. Tumori. 2016;102(2):162–7.CrossRef
24.
go back to reference Liu RZ, Zhao ZR, Ng CS. Statistical modelling for thoracic surgery using a nomogram based on logistic regression. J Thorac Dis. 2016;8(8):E731–6.CrossRef Liu RZ, Zhao ZR, Ng CS. Statistical modelling for thoracic surgery using a nomogram based on logistic regression. J Thorac Dis. 2016;8(8):E731–6.CrossRef
25.
go back to reference Fukushima T, Ogura K, Akiyama T, Takeshita K, Kawai A. Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan. BMC Musculoskelet Disord. 2018;19(1):297.CrossRef Fukushima T, Ogura K, Akiyama T, Takeshita K, Kawai A. Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan. BMC Musculoskelet Disord. 2018;19(1):297.CrossRef
26.
go back to reference Chen LD, Liang JY, Wu H, Wang Z, Li SR, Li W, Zhang XH, Chen JH, Ye JN, Li X, et al. Multiparametric radiomics improve prediction of lymph node metastasis of rectal cancer compared with conventional radiomics. Life Sci. 2018;208:55–63.CrossRef Chen LD, Liang JY, Wu H, Wang Z, Li SR, Li W, Zhang XH, Chen JH, Ye JN, Li X, et al. Multiparametric radiomics improve prediction of lymph node metastasis of rectal cancer compared with conventional radiomics. Life Sci. 2018;208:55–63.CrossRef
27.
go back to reference Tan X, Ma Z, Yan L, Ye W, Liu Z, Liang C. Radiomics nomogram outperforms size criteria in discriminating lymph node metastasis in resectable esophageal squamous cell carcinoma. Eur Radiol. 2019;29(1):392–400.CrossRef Tan X, Ma Z, Yan L, Ye W, Liu Z, Liang C. Radiomics nomogram outperforms size criteria in discriminating lymph node metastasis in resectable esophageal squamous cell carcinoma. Eur Radiol. 2019;29(1):392–400.CrossRef
28.
go back to reference Asuncion Esteve-Pastor M, Miguel Rivera-Caravaca J, Roldan V, Vicente V, Valdes M, Marin F, Lip GYH. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores. Thromb Haemost. 2017;117(10):1848–58.CrossRef Asuncion Esteve-Pastor M, Miguel Rivera-Caravaca J, Roldan V, Vicente V, Valdes M, Marin F, Lip GYH. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores. Thromb Haemost. 2017;117(10):1848–58.CrossRef
29.
go back to reference Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Vicente V, Valdes M, Marin F, Lip GYH. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores. The Murcia atrial fibrillation project. Thromb Haemost. 2017;117(10):1848–58.CrossRef Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Vicente V, Valdes M, Marin F, Lip GYH. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores. The Murcia atrial fibrillation project. Thromb Haemost. 2017;117(10):1848–58.CrossRef
30.
go back to reference Garcia-Fernandez A, Roldan V, Rivera-Caravaca JM, Hernandez-Romero D, Valdes M, Vicente V, Lip GY, Marin F. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep. 2017;7:41565.CrossRef Garcia-Fernandez A, Roldan V, Rivera-Caravaca JM, Hernandez-Romero D, Valdes M, Vicente V, Lip GY, Marin F. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep. 2017;7:41565.CrossRef
31.
go back to reference Rodrigues G, Gonzalez-Maldonado S, Bauman G, Senan S, Lagerwaard F. A statistical comparison of prognostic index systems for brain metastases after stereotactic radiosurgery or fractionated stereotactic radiation therapy. Clin Oncol (R Coll Radiol). 2013;25(4):227–35.CrossRef Rodrigues G, Gonzalez-Maldonado S, Bauman G, Senan S, Lagerwaard F. A statistical comparison of prognostic index systems for brain metastases after stereotactic radiosurgery or fractionated stereotactic radiation therapy. Clin Oncol (R Coll Radiol). 2013;25(4):227–35.CrossRef
32.
go back to reference Zhang WT, Zhang WW, He ZY, Sun JY, Zhang L, Xia Q, Wu SG. Comparison of the effects of local treatment strategies in non-metastatic Ewing sarcoma of bone. Expert Rev Anticancer Ther. 2018;18(5):501–6.CrossRef Zhang WT, Zhang WW, He ZY, Sun JY, Zhang L, Xia Q, Wu SG. Comparison of the effects of local treatment strategies in non-metastatic Ewing sarcoma of bone. Expert Rev Anticancer Ther. 2018;18(5):501–6.CrossRef
33.
go back to reference Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10.CrossRef Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10.CrossRef
34.
go back to reference Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with high-grade osteosarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(4):593–9.CrossRef Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with high-grade osteosarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(4):593–9.CrossRef
Metadata
Title
A nomogram for determining the disease-specific survival in Ewing sarcoma: a population study
Authors
Jun Zhang
Zhenyu Pan
Jin Yang
Xiaoni Yan
Yuanjie Li
Jun Lyu
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Sarcoma
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5893-9

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine